NDA 008762 · Viatris
Dilantin-125
Phenytoin · Oral · Anti-epileptic Agent
Last checked: Nov 19, 2026Latest source record: Mar 3, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1953
Jan 6, 1953
Approved uses
1
Original approval plus efficacy supplements
Registered trials
113
17 Phase 3, 6 recruiting
FAERS reports
20,902
18,748 serious, 2,991 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 24, 2024.
Phenytoin is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. ( 1 )
Mechanism: The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 6, 1953 Original approval · Type 2 - New Active Ingredient
2 products under this application
- DILANTIN-125 · PHENYTOIN 125MG/5ML · SUSPENSION, ORAL · Prescription · TE AB
- DILANTIN-30 · PHENYTOIN 30MG/5ML · SUSPENSION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Phenytoin" as an intervention, any sponsor and status, largest first.
- Pharmacological Management of Seizures Post Traumatic Brain InjuryPivotal-lookingNot yet recruiting
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT04573803 · 1,649 participants (planned) · Start Mar 1, 2021 · Primary completion Mar 1, 2026
Drug: Phenytoin Sodium; Levetiracetam · For: Traumatic Brain Injury; Post Traumatic Seizures
- Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)Pivotal-lookingRecruiting
All India Institute of Medical Sciences, JodhpurGovernment (non-federal)
NCT07072624 · 1,260 participants (planned) · Start Jul 23, 2025 · Primary completion Mar 15, 2027
Drug: Phenytoin; Levetiracetam and 1 more · For: Seizures; Traumatic Brain Injuries; Traumatic Brain Injury (TBI) Patients
Sites: Chandigarh, India; Jodhpur, India; Lucknow, India
- Evaluation of CYP2C9 ActivityStatus unknown
Hadassah Medical OrganizationAcademic, hospital or other
NCT00162461 · 1,200 participants (planned) · Start Aug 1998 · Primary completion Dec 2020
Drug: Phenytoin single dose (300 mg) · For: Healthy
Sites: Jerusalem, Israel
- Determinants of Warfarin MetabolismRecruiting
Hadassah Medical OrganizationAcademic, hospital or other
NCT00162474 · 1,000 participants (planned) · Start Sep 2003 · Primary completion Dec 2030
Drug: Warfarin; Phenytoin and 4 more · For: Healthy
Sites: Jerusalem, Israel
- A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic CancerPivotal-lookingCompleted
Pancreatic Cancer Action NetworkAcademic, hospital or other
NCT04229004 · 502 participants · Start Jan 31, 2020 · Primary completion Feb 5, 2025
Drug: Gemcitabine combined with nab-paclitaxel; Dose -mFOLFIRINOX and 3 more · For: Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
- Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status EpilepticusPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01870024 · 434 participants · Start Jun 26, 2013 · Primary completion Feb 23, 2018
Drug: Clonazepam; Fosphenytoin and 2 more · For: Status Epilepticus; Epilepsy
Sites: Paris, France
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic SeizuresPivotal-lookingCompleted
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT00004817 · 385 participants · Start Feb 1991
Drug: phenytoin; valproate sodium · For: Post-Traumatic Seizure Disorder; Head Injuries
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,771
- drug interaction1,580
- seizure1,426
- toxicity to various agents1,372
- convulsion1,260
- off label use1,140
- status epilepticus812
- stevens-johnson syndrome771
- pyrexia686
- fall618
- dizziness606
- drug reaction with eosinophilia and systemic symptoms603
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 569 |
| 2005 | 621 |
| 2006 | 433 |
| 2007 | 499 |
| 2008 | 682 |
| 2009 | 659 |
| 2010 | 895 |
| 2011 | 1,213 |
| 2012 | 1,038 |
| 2013 | 1,000 |
| 2014 | 907 |
| 2015 | 989 |
| 2016 | 929 |
| 2017 | 1,102 |
| 2018 | 1,201 |
| 2019 | 1,250 |
| 2020 | 1,232 |
| 2021 | 1,121 |
| 2022 | 1,114 |
| 2023 | 1,131 |
| 2024 | 988 |
| 2025 | 867 |
| 2026 | 462 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dilantin-125 (Phenytoin)
2024 spending
$151K
Beneficiaries
86
428 claims
Per beneficiary
$1,756
$0.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,904 |
| 2021 | $181,085 |
| 2022 | $197,071 |
| 2023 | $186,396 |
| 2024 | $150,995 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures.
Pressler RM, Abend NS, Auvin S, et al. · Epilepsia 2023 · Systematic Review, Meta-Analysis
- Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA, Gilmore EJ, Johnson EL, et al. · Neurocrit Care 2024 · Systematic Review, Practice Guideline
- Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis.
Milosavljevic F, Manojlovic M, Matkovic L, et al. · JAMA Netw Open 2024 · Systematic Review, Meta-Analysis
- Antiseizure Medications in Poststroke Seizures: A Systematic Review and Network Meta-Analysis.
Misra S, Wang S, Quinn TJ, et al. · Neurology 2025 · Systematic Review, Network Meta-Analysis
- Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ, Sudell M, Cividini S, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Systematic Review
- Comparative efficacy and safety of second-line medications for status epilepticus: A network meta-analysis.
Zhang Q, Peng S, Wei Z, et al. · Medicine (Baltimore) 2024 · Comparative Study, Systematic Review
Sponsor: Viatris · Also marketed as Dilantin-30
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.